Rheolytic thrombectomy market seen reaching $1.9B by 2030

The rheolytic thrombectomy market is projected to grow from $1.14 billion in 2025 to $1.26 billion in 2026, then reach $1.9 billion by 2030, driven by rising cardiovascular disease, thrombotic disorders and demand for faster clot removal. North America led the market in 2025, while Asia-Pacific is forecast to be the fastest-growing region.

Why it matters: - Rheolytic thrombectomy is positioned as a fast, minimally invasive option for removing dangerous blood clots in conditions such as deep vein thrombosis and pulmonary embolism. - The market’s growth reflects broader demand for vascular interventions that can restore blood flow quickly and reduce ischemic damage. - Rising case volumes and an aging population are expanding the need for clot-removal procedures.

What happened: - The Business Research Company released a forecast on the rheolytic thrombectomy market on July 22, 2026. - The report says the market will grow from $1.14 billion in 2025 to $1.26 billion in 2026, a 10.6% CAGR. - The market is projected to reach $1.9 billion by 2030, at a 10.9% CAGR. - The report includes a free sample and the full report.

The details: - Rheolytic thrombectomy uses a high-velocity saline jet system to break up a clot and suction away debris. - The procedure is designed to restore normal blood flow in blocked vessels. - The report links market growth to rising thrombotic disorders, higher cardiovascular disease prevalence, broader use of minimally invasive procedures, vascular intervention technology upgrades and more specialized vascular treatment centers. - Expected growth drivers through 2030 include more cases of deep vein thrombosis and pulmonary embolism, greater demand for rapid clot removal, investment in healthcare infrastructure and more image-guided vascular interventions. - Anticipated trends include better catheter-based clot removal, more efficient saline jet systems, faster revascularization techniques and expanded use in peripheral vascular interventions. - The report says cardiovascular disease is a key growth driver because rheolytic thrombectomy can clear blocked vessels, restore blood flow and improve recovery outcomes. - The UK’s Joint Strategic Needs Assessment reported 185 cardiovascular disease deaths in 2023, up from 178 in 2022. - NHS England reported in the third quarter of 2025 that venous thromboembolism risk assessments covered 92% of admitted patients. - The World Health Organization said in February 2025 that the global population aged 60 and above is expected to rise from 1.1 billion in 2023 to 1.4 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing region over the coming years. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report frames rheolytic thrombectomy as part of a broader shift toward minimally invasive vascular care. - Growth looks tied not just to disease burden, but to healthcare systems adopting faster, more targeted intervention tools. - The emphasis on aging demographics suggests demand may remain durable even if procedure volumes fluctuate by region.

What's next: - The market is expected to keep expanding as hospitals add advanced clot-removal capability and image-guided interventions spread. - Asia-Pacific may narrow the gap with North America if healthcare buildout and awareness of minimally invasive treatment continue to rise. - The report points to further product development in catheter systems and saline jet technology as the next competitive focus. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated trend graphics. - The company says it offers more than 30,000 reports across 27 industries and 60+ geographies, supported by 1,500,000 datasets.